IDH2 and lymphoma: Surprisingly, as opposed to first studies (DiNardo et al., Leuk Lymphoma, 2014; [43]), AML and myelodysplastic patients with IDH mutations did not display a better response to AZA monotherapy in more recent reports [44,45,46].